Ferenc, Christopher B.
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`FilingDate:
`FilingFolder:
`
`FilingDocumentID:
`
`Counsel:
`
`Trials <Trials@USPTO.GOV>
`Wednesday, April 24, 2019 3:17 PM
`Ferenc, Christopher B.
`Feldstein, Mark; McCurdy, Barbara; Sommers, Erin; DeRoo, Pier;
`BMWhite@perkinscoie.com; EGreb@perkinscoie.com; Sodikoff, Brian
`RE: IPR2019-00789
`
`4/25/2019 7:03:00 AM
`\Sawai Pharmaceutical - Opinion for Dimethyl Fumarate (385667-00004)\1. Official
`Matter Records (385667-00004)
`!nrtdms:0:!session:LOCAL:!database:US:!document:139131497,1:
`
`The panel has received Sawai's Motion for Joinder. The panel understands that, if joined to the Mylan IPR (IPR2018-
`01403), Sawai does not intend to produce its own testifying witnesses or file substantive papers in the Mylan IPR so long
`as Mylan remains a party to the case. In this situation, the panel advises Sawai to file its Reply in the normal course, and
`to indicate in the Reply that it has contacted Mylan but not received a response, if that remains the case. The panel can
`revisit the matter should the declarant situation become an issue when deciding Sawai's Motion for Joinder. A
`teleconference is not necessary if the above is agreeable to the parties.
`
`Best regards,
`Eric W. Hawthorne
`Supervisory Paralegal Specialist
`Patent Trial and Appeal Board
`
`-----Original Message-----
`From: Ferenc, Christopher B. <christopher.ferenc@kattenlaw.com>
`Sent: Friday, April 19, 2019 7:44 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: Feldstein, Mark <mark.feldstein@finnegan.com>; McCurdy, Barbara <barbara.mccurdy@finnegan.com>; Sommers,
`Erin <Erin.Sommers@finnegan.com>; DeRoo, Pier <Pier.DeRoo@finnegan.com>; BMWhite@perkinscoie.com;
`EGreb@perkinscoie.com; Sodikoff, Brian <brian.sodikoff@kattenlaw.com>
`Subject: Re: IPR2019-00789
`
`Dear PTAB,
`
`We represent petitioners Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. (together “Sawai”) in the pending inter partes
`review, Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. v. Biogen MA, Inc., IPR2019-00789. As you are aware, Sawai
`filed a Motion for Joinder pursuant to 35 U.S.C. § 315(c) and 37 C.F.R § 42.122(b) requesting joinder with a pending inter
`partes review filed by Mylan Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc. v. Biogen MA Inc., IPR2018-01403
`(“Mylan IPR”).
`
`We are following up on the Board’s April 12th correspondence (below) requesting Sawai to check back in with the Board
`regarding Sawai’s request for a telephone conference with the Board. It is Sawai’s understanding that the panel for
`IPR2019-00789 would be the same as the Mylan IPR. Thus, Sawai requests a telephone conference between the parties
`
`1
`
`Sawai (IPR2019-00789) Ex. 1062, p. 001
`
`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`FilingDate:
`FilingFolder:
`
`FilingDocumentID:
`
`Counsel:
`
`Trials <Trials@USPTO.GOV>
`Wednesday, April 24, 2019 3:17 PM
`Ferenc, Christopher B.
`Feldstein, Mark; McCurdy, Barbara; Sommers, Erin; DeRoo, Pier;
`BMWhite@perkinscoie.com; EGreb@perkinscoie.com; Sodikoff, Brian
`RE: IPR2019-00789
`
`4/25/2019 7:03:00 AM
`\Sawai Pharmaceutical - Opinion for Dimethyl Fumarate (385667-00004)\1. Official
`Matter Records (385667-00004)
`!nrtdms:0:!session:LOCAL:!database:US:!document:139131497,1:
`
`The panel has received Sawai's Motion for Joinder. The panel understands that, if joined to the Mylan IPR (IPR2018-
`01403), Sawai does not intend to produce its own testifying witnesses or file substantive papers in the Mylan IPR so long
`as Mylan remains a party to the case. In this situation, the panel advises Sawai to file its Reply in the normal course, and
`to indicate in the Reply that it has contacted Mylan but not received a response, if that remains the case. The panel can
`revisit the matter should the declarant situation become an issue when deciding Sawai's Motion for Joinder. A
`teleconference is not necessary if the above is agreeable to the parties.
`
`Best regards,
`Eric W. Hawthorne
`Supervisory Paralegal Specialist
`Patent Trial and Appeal Board
`
`-----Original Message-----
`From: Ferenc, Christopher B. <christopher.ferenc@kattenlaw.com>
`Sent: Friday, April 19, 2019 7:44 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: Feldstein, Mark <mark.feldstein@finnegan.com>; McCurdy, Barbara <barbara.mccurdy@finnegan.com>; Sommers,
`Erin <Erin.Sommers@finnegan.com>; DeRoo, Pier <Pier.DeRoo@finnegan.com>; BMWhite@perkinscoie.com;
`EGreb@perkinscoie.com; Sodikoff, Brian <brian.sodikoff@kattenlaw.com>
`Subject: Re: IPR2019-00789
`
`Dear PTAB,
`
`We represent petitioners Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. (together “Sawai”) in the pending inter partes
`review, Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. v. Biogen MA, Inc., IPR2019-00789. As you are aware, Sawai
`filed a Motion for Joinder pursuant to 35 U.S.C. § 315(c) and 37 C.F.R § 42.122(b) requesting joinder with a pending inter
`partes review filed by Mylan Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc. v. Biogen MA Inc., IPR2018-01403
`(“Mylan IPR”).
`
`We are following up on the Board’s April 12th correspondence (below) requesting Sawai to check back in with the Board
`regarding Sawai’s request for a telephone conference with the Board. It is Sawai’s understanding that the panel for
`IPR2019-00789 would be the same as the Mylan IPR. Thus, Sawai requests a telephone conference between the parties
`
`1
`
`Sawai (IPR2019-00789) Ex. 1062, p. 001
`
`
`
`and Judges Snedden, Chagnon and Hawlow, the panel assigned to IPR2018-01403. As explained in Sawai’s motion for
`Joinder in IPR2019-00789 (Paper 2), Sawai seeks Mylan’s permission to use the same experts Mylan used in IPR2018-
`01403. Over the past few weeks, Sawai has made numerous efforts (including emails and voice mails to Mylan’s
`counsel) to get Mylan’s position on whether Mylan will allow Sawai to use its experts. Mylan has refused to answer one
`way or another. (Sawai is willing to provide the PTAB with copies of its email correspondence to counsel for Mylan upon
`request of the PTAB.)
`
`Sawai requests a conference with Judges Snedden, Chagnon and Hawlow, and asks the panel to Order Mylan to provide
`its answer. Sawai needs this information so that it can properly respond in its Reply to Patent Owner’s Opposition to
`Motion for joinder. As stated in Sawai’s previous emails to the PTAB, during any conference call with the PTAB, Sawai
`welcomes any additional instructions from the PTAB regarding the Motion for Joinder.
`
`Best regards,
`
`Chris Ferenc
`Counsel for Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd.
`
`Christopher B. Ferenc
`Associate
`Katten Muchin Rosenman LLP
`2900 K Street NW
`Suite 200
`Washington, DC. 20007
`(202) 625-3647
`christopher.ferenc@kattenlaw.com<mailto:christopher.ferenc@kattenlaw.com>
`
`On Apr 12, 2019, at 10:37 AM, Trials <Trials@uspto.gov<mailto:Trials@uspto.gov>> wrote:
`
`Counsel: We do not have a panel for this case yet. Please check back this time next week.
`
`Thank you,
`Eric W. Hawthorne
`Supervisory Paralegal Specialist
`Patent Trial and Appeal Board
`
`From: Ferenc, Christopher B. <christopher.ferenc@kattenlaw.com<mailto:christopher.ferenc@kattenlaw.com>>
`Sent: Friday, April 12, 2019 10:27 AM
`To: Trials <Trials@USPTO.GOV<mailto:Trials@USPTO.GOV>>
`Cc: Feldstein, Mark <mark.feldstein@finnegan.com<mailto:mark.feldstein@finnegan.com>>; McCurdy, Barbara
`<barbara.mccurdy@finnegan.com<mailto:barbara.mccurdy@finnegan.com>>; Sommers, Erin
`<Erin.Sommers@finnegan.com<mailto:Erin.Sommers@finnegan.com>>; DeRoo, Pier
`<Pier.DeRoo@finnegan.com<mailto:Pier.DeRoo@finnegan.com>>;
`BMWhite@perkinscoie.com<mailto:BMWhite@perkinscoie.com>;
`EGreb@perkinscoie.com<mailto:EGreb@perkinscoie.com>; Sodikoff, Brian
`<brian.sodikoff@kattenlaw.com<mailto:brian.sodikoff@kattenlaw.com>>
`Subject: RE: IPR2019-00789
`
`Dear PTAB,
`
`2
`
`Sawai (IPR2019-00789) Ex. 1062, p. 002
`
`
`
`We represent petitioners Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. (together “Sawai”) in the pending inter partes
`review, Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. v. Biogen MA, Inc., IPR2019-00789. As you are aware, Sawai
`filed a Motion for Joinder pursuant to 35 U.S.C. § 315(c) and 37 C.F.R § 42.122(b) requesting joinder with a pending inter
`partes review filed by Mylan Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc. v. Biogen MA Inc., IPR2018-01403
`(“Mylan IPR”).
`
`We are following up on the Board’s March 26th correspondence (below) requesting Sawai to check back in with the
`Board regarding Sawai’s request for a telephone conference with the Board. Specifically, Sawai requests a telephone
`conference between the parties and Judges Snedden, Chagnon and Hawlow, the panel assigned to IPR2018-01403. As
`explained in Sawai’s motion for Joinder in IPR2019-00789 (Paper 2), Sawai seeks Mylan’s permission to use the same
`experts Mylan used in IPR2018-01403. Over the past few weeks, Sawai has made numerous efforts (including emails
`and voice mails to Mylan’s counsel) to get Mylan’s position on whether Mylan will allow Sawai to use its experts. Mylan
`has refused to answer one way or another. (Sawai is willing to provide the PTAB with copies of its email correspondence
`to counsel for Mylan upon request of the PTAB.)
`
`Sawai requests a conference with Judges Snedden, Chagnon and Hawlow, and asks the panel to Order Mylan to provide
`its answer. Sawai needs this information so that it can properly respond in its Reply to Patent Owner’s Opposition to
`Motion for joinder. As stated Sawai’s email to the PTAB on March 26th, during any conference call with the PTAB, Sawai
`welcomes any additional instructions from the PTAB regarding the Motion for Joinder.
`
`Best regards,
`
`Chris Ferenc
`Counsel for Sawai USA, Inc. and Sawai
`
`Christopher B. Ferenc
`Associate
`Katten Muchin Rosenman LLP
`2900 K Street NW, North Tower - Suite 200 / Washington, DC 20007-5118 p / +1.202.625.3647 f / +1.202.339.6044
`christopher.ferenc@kattenlaw.com<mailto:christopher.ferenc@kattenlaw.com> /
`https://gcc01.safelinks.protection.outlook.com/?url=www.kattenlaw.com&data=02%7C01%7Ctrials%40uspto.gov
`%7C8fddc872b152437f296708d6c4bc5ec6%7Cff4abfe983b540268b8ffa69a1cad0b8%7C1%7C0%7C63691271066633059
`5&sdata=5s2vnxGbfc8ozsYtlv2f8kwarCq5y8%2BQ6s1TE%2FpfUKQ%3D&reserved=0<https://gcc01.safelinks.pr
`otection.outlook.com/?url=http%3A%2F%2Fwww.kattenlaw.com&data=02%7C01%7Ctrials%40uspto.gov%7C8fddc
`872b152437f296708d6c4bc5ec6%7Cff4abfe983b540268b8ffa69a1cad0b8%7C1%7C0%7C636912710666340599&s
`data=Tr08HDJ%2Fme67ferRwLvcGaQyBPARIKERRYkB1pnKZ2Q%3D&reserved=0>
`From: Trials <Trials@USPTO.GOV<mailto:Trials@USPTO.GOV>>
`Sent: Tuesday, March 26, 2019 12:46 PM
`To: Ferenc, Christopher B. <christopher.ferenc@kattenlaw.com<mailto:christopher.ferenc@kattenlaw.com>>; Trials
`<Trials@USPTO.GOV<mailto:Trials@USPTO.GOV>>
`Cc: Feldstein, Mark <mark.feldstein@finnegan.com<mailto:mark.feldstein@finnegan.com>>; McCurdy, Barbara
`<barbara.mccurdy@finnegan.com<mailto:barbara.mccurdy@finnegan.com>>; Sommers, Erin
`<Erin.Sommers@finnegan.com<mailto:Erin.Sommers@finnegan.com>>; DeRoo, Pier
`<Pier.DeRoo@finnegan.com<mailto:Pier.DeRoo@finnegan.com>>;
`BMWhite@perkinscoie.com<mailto:BMWhite@perkinscoie.com>;
`EGreb@perkinscoie.com<mailto:EGreb@perkinscoie.com>; Sodikoff, Brian
`<brian.sodikoff@kattenlaw.com<mailto:brian.sodikoff@kattenlaw.com>>
`Subject: RE: IPR2019-00789
`
`Counsel: We do not have a panel for this case yet. Please check back in a couple of weeks.
`Thank you,
`
`3
`
`Sawai (IPR2019-00789) Ex. 1062, p. 003
`
`
`
`Maria King
`Deputy Chief Clerk for Trials
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`703-756-1288
`
`From: Ferenc, Christopher B. <christopher.ferenc@kattenlaw.com<mailto:christopher.ferenc@kattenlaw.com>>
`Sent: Tuesday, March 26, 2019 12:32 PM
`To: Trials <Trials@USPTO.GOV<mailto:Trials@USPTO.GOV>>
`Cc: Feldstein, Mark <mark.feldstein@finnegan.com<mailto:mark.feldstein@finnegan.com>>; McCurdy, Barbara
`<barbara.mccurdy@finnegan.com<mailto:barbara.mccurdy@finnegan.com>>; Sommers, Erin
`<Erin.Sommers@finnegan.com<mailto:Erin.Sommers@finnegan.com>>; DeRoo, Pier
`<Pier.DeRoo@finnegan.com<mailto:Pier.DeRoo@finnegan.com>>;
`BMWhite@perkinscoie.com<mailto:BMWhite@perkinscoie.com>;
`EGreb@perkinscoie.com<mailto:EGreb@perkinscoie.com>; Sodikoff, Brian
`<brian.sodikoff@kattenlaw.com<mailto:brian.sodikoff@kattenlaw.com>>
`Subject: IPR2019-00789
`
`Your Honors:
`
`We represent petitioners Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. (together “Sawai”) in the pending inter partes
`review, Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd. v. Biogen MA, Inc., IPR2019-00789. As you are aware, Sawai
`filed a Motion for Joinder pursuant to 35 U.S.C. § 315(c) and 37 C.F.R § 42.122(b) requesting joinder with a pending inter
`partes review filed by Mylan Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc. v. Biogen MA Inc., IPR2018-01403
`(“Mylan IPR”).
`
`All parties are in the process of setting up a meet and confer to discuss Sawai’s pending joinder motion. Ahead of the
`meet and confer, Sawai wanted to know if the panel had any additional instructions regarding the Motion for Joinder
`that the parties should discuss during any meet and confer.
`
`Counsel for all parties has been copied on this email and were provided a copy for prior consideration. Without further
`elaboration, (only) counsel for Biogen responded as follows: “Biogen believes that Sawai’s proposed email to the Board
`is improper at this time.”
`
`Best regards,
`
`Chris Ferenc
`Counsel for Sawai USA, Inc. and Sawai Pharmaceuticals, Ltd.
`
`Christopher B. Ferenc
`Associate
`Katten Muchin Rosenman LLP
`2900 K Street NW, North Tower - Suite 200 / Washington, DC 20007-5118 p / +1.202.625.3647 f / +1.202.339.6044
`christopher.ferenc@kattenlaw.com<mailto:christopher.ferenc@kattenlaw.com> /
`https://gcc01.safelinks.protection.outlook.com/?url=www.kattenlaw.com&data=02%7C01%7Ctrials%40uspto.gov
`%7C8fddc872b152437f296708d6c4bc5ec6%7Cff4abfe983b540268b8ffa69a1cad0b8%7C1%7C0%7C63691271066634059
`9&sdata=cMtojMPEIaVKd8dtq%2Fa8SLyAWeayQnL4SnK8b34VaKA%3D&reserved=0<https://gcc01.safelinks.p
`rotection.outlook.com/?url=http%3A%2F%2Fwww.kattenlaw.com&data=02%7C01%7Ctrials%40uspto.gov%7C8fdd
`c872b152437f296708d6c4bc5ec6%7Cff4abfe983b540268b8ffa69a1cad0b8%7C1%7C0%7C636912710666340599&
`sdata=Tr08HDJ%2Fme67ferRwLvcGaQyBPARIKERRYkB1pnKZ2Q%3D&reserved=0>
`
`4
`
`Sawai (IPR2019-00789) Ex. 1062, p. 004
`
`
`
`===========================================================
`
`CONFIDENTIALITY NOTICE:
`
`This electronic mail message and any attached files contain information intended for the exclusive
`
`use of the individual or entity to whom it is addressed and may contain information that is
`
`proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you
`
`are not the intended recipient, you are hereby notified that any viewing, copying, disclosure or
`
`distribution of this information may be subject to legal restriction or sanction. Please notify
`
`the sender, by electronic mail or telephone, of any unintended recipients and delete the original
`
`message without making any copies.
`
`===========================================================
`
`NOTIFICATION: Katten Muchin Rosenman LLP is an Illinois limited liability partnership that has
`
`elected to be governed by the Illinois Uniform Partnership Act (1997).
`
`===========================================================
`
`5
`
`Sawai (IPR2019-00789) Ex. 1062, p. 005
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
